Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided by a 7% increase in sales.
Fourth-quarter worldwide sales increased 7% year-over-year to $15.6 billion, with Pharmaceutical and Animal Health revenues growing 7% and 9% respectively.
The company reported a net profit of $3.74 billion or $1.48 per share for the December quarter, compared to a loss of $1.23 billion or $0.48 per share in the prior-year period. On an adjusted basis, earnings climbed to $1.72 per share in Q4 from $0.03 per share in the fourth quarter of 2023.
“Our business remains well-positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential,” said Merck’s CEO Robert Davis.
Prior Performance
The post MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth first appeared on AlphaStreet.
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided by a 7% increase in sales. Fourth-quarter worldwide
The post MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth first appeared on AlphaStreet.
Categories AlphaGraphs, Earnings, Health Care
MRK Earnings: Merck Q4 2024 adj. profit jumps on strong sales growth
Pharmaceutical company Merck & Co. Inc. (NYSE: MRK) reported a sharp increase in adjusted earnings for the fourth quarter of 2024, aided by a 7% increase in sales.
Fourth-quarter worldwide sales increased 7% year-over-year to $15.6 billion, with Pharmaceutical and Animal Health revenues growing 7% and 9% respectively.
The company reported a net profit of $3.74 billion or $1.48 per share for the December quarter, compared to a loss of $1.23 billion or $0.48 per share in the prior-year period. On an adjusted basis, earnings climbed to $1.72 per share in Q4 from $0.03 per share in the fourth quarter of 2023.
“Our business remains well-positioned thanks to the dedication of our talented global team, and I am more confident than ever in our long-term growth potential,” said Merck’s CEO Robert Davis.
Prior Performance
Listen to the conference calls as they happen. Don’t miss a beat! With AlphaStreet Intelligence, you can listen to live calls and interviews as they happen, so you never have to worry about missing out on important information.
Most Popular
Key highlights from Estée Lauder’s (EL) Q2 2025 earnings results
The Estée Lauder Companies Inc. (NYSE: EL) reported its second quarter 2025 earnings results today. Net sales decreased 6% year-over-year to $4 billion. Organic sales were also down 6%. Net
PayPal Holdings (PYPL) Q4 2024 Earnings: Key financials and quarterly highlights
PayPal Holdings, Inc. (NASDAQ: PYPL) reported its fourth quarter 2024 earnings results today. Net revenues increased 4% year-over-year to $8.4 billion. Revenue growth was 4% on a currency-neutral basis. GAAP
PFE Earnings: Key quarterly highlights from Pfizer’s Q4 2024 financial results
Pfizer Inc. (NYSE: PFE) reported its fourth quarter 2024 earnings results today. Revenues increased 22% year-over-year to $17.8 billion. GAAP net income was $410 million, or $0.07 per share, compared
Tags
Discover more from World Byte News
Subscribe to get the latest posts sent to your email.
